CTOs on the Move

Quit Genius

www.quitgenius.com

 
Quit Genius is on a mission to empower people to quit their addictions and become the best version of themselves.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Jeffrey Thomas
Director, Information Security Officer Profile

Funding

Quit Genius raised $11M on 03/18/2020

Similar Companies

Delta Health Systems

Delta Health Systems is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Stanford Hospital and Clinics

Stanford Hospital and Clinics is located on the northern end of the Stanford University campus in Palo Alto, California.

ROWI

ROWI Teen is a mental health treatment center for teens and adolescents, specializing in mental health issues like depression, anxiety, OCD, and ASD.

Broadmoor

Broadmoor is a Fort Pierce, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.